CYTH Cyclo Therapeutics Dashboard

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

Company profile

Ticker

CYTH, CYTHW

Exchange

NASDAQ

Website

www.cyclotherapeutics.com

CEO

Nathan Scott Fine

Incorporated

Florida

Location

Florida

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Industrial Organic Chemicals

LyondellBasell Industries • Union Carbide • Westlake Chemical • International Flavors & Fragrances • Sensient Technologies • Green Plains • NewMarket • Westlake Chemical Partners • Renewable Energy • REX American Resources ...

Former names

CTD HOLDINGS INC, CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC

SEC CIK

0000922247

Corporate docs

Articles of Incorporation & Bylaws

IRS number

593029743

CYTH stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Cyclo Therapeutics Commences Commercial-Scale Manufacturing For Trappsol Cyclo

27 Jul 21

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

22 Jun 21

Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo

17 Jun 21

Cyclo Therapeutics Highlights Launch Of New Website

15 Jun 21

12 Health Care Stocks Moving In Monday's After-Market Session

14 Jun 21

Press releases

Pro users get this 30m faster

Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™

27 Jul 21

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

21 Jun 21

Company to discuss clinical progress of Trappsol® Cyclo™ development program for the treatment of Niemann-Pick Disease Type C (NPC) Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the

Thinking about buying stock in AMC Entertainment, AnPac Bio-Medical Science, General Electric, JPMorgan, or Cyclo Therapeutics?

18 Jun 21

NEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, ANPC, GE, JPM, and CYTH.

Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?

17 Jun 21

Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

17 Jun 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

14 May 21

29 Jul 21

31 Dec 21

Financial summary

Financial statements Chart CYTH financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	15.51M	15.51M	15.51M	15.51M	15.51M	15.51M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	1.35M	863.05K	1.64M	971.48K
Cash used (since last report)	n/a	n/a	5.33M	3.42M	6.5M	3.85M
Cash remaining	n/a	n/a	10.18M	12.09M	9M	11.66M
Runway (months of cash)	n/a	n/a	7.6	14.0	5.5	12.0

Beta Read what these cash burn values mean

Recent insider trades

CYTH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
18 Jun 21	Sieger Markus	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	6	2,500	15K	40,000
18 Jun 21	Sieger Markus	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	6.5	7,500	48.75K	37,500
21 May 21	Ostronic Francis Patrick	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	3.25	100	325	100
21 May 21	Sieger Markus	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	3.65	3,482	12.71K	30,000
20 May 21	Sieger Markus	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	3.19	2,312	7.38K	26,518
19 May 21	Sieger Markus	Warrant to Purchase Common Stock Common Stock	Buy	Aquire P	No	No	3.01	9,206	27.71K	24,206
16 Apr 21	Ostronic Francis Patrick	Common Stock	Buy	Aquire P	No	No	6.3	5,000	31.5K	76,559
16 Apr 21	Ostronic Francis Patrick	Common Stock	Buy	Aquire P	No	No	6.75	5,000	33.75K	71,559

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

CYTH institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

15.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	10	1	+900.0%
Opened positions	10	1	+900.0%
Closed positions	1	1	–
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	2.58M	4K	+64425.0%
Total shares	1.01M	30K	+3271.5%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Hirschman Orin	418K	$0	NEW
AIGH Capital Management	350K	$1.52M	NEW
Armistice Capital	100K	$435K	NEW
Worth Venture Partners	88.69K	$386K	NEW
Jane Street	27.89K	$121K	NEW
Susquehanna International	15.66K	$68K	NEW
GS Goldman Sachs	10.28K	$45K	NEW
RY Royal Bank Of Canada	746	$3K	NEW
Captrust Financial Advisors	100	$0	NEW
MS Morgan Stanley	90	$0	NEW

Largest transactions	Shares	Bought/sold	Change
Hirschman Orin	418K	+418K	NEW
AIGH Capital Management	350K	+350K	NEW
Armistice Capital	100K	+100K	NEW
Worth Venture Partners	88.69K	+88.69K	NEW
Wendell David Associates	0	-30K	EXIT
Jane Street	27.89K	+27.89K	NEW
Susquehanna International	15.66K	+15.66K	NEW
GS Goldman Sachs	10.28K	+10.28K	NEW
RY Royal Bank Of Canada	746	+746	NEW
Captrust Financial Advisors	100	+100	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Orphazyme A/S

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: apparent, bringing, Chief, contingent, critical, CYTH, event, half, investor, issuer, LLC, moving, Nasdaq, neurocognitive, nonemployee, notification, option, ordinary, par, percent, pivotal, public, pursue, readily, regional, seasoned, split, Standard

Removed: added, adjustable, adjusted, administrative, advisory, agent, agreed, alternative, anniversary, annually, arrangement, avoid, borrow, borrowing, broad, carryforward, clarifying, collateralized, commencement, Comparative, Consumer, continuing, contractually, corporate, declared, decrease, delay, dependent, dilution, discharge, discount, division, doubt, downsize, eliminate, exceeded, extend, FASB, fee, financing, fixed, Fordham, general, hand, handful, inception, Index, infrastructure, insolvency, introduced, lack, lease, LIQUIDITY, listing, middle, million, minimum, narrow, noted, obligated, offer, opening, outcome, ownership, package, pay, permitted, practical, predominantly, prior, quantifiable, register, registration, reimbursement, removing, rent, representing, retrospective, scope, select, simplify, Simplifying, substantial, ThinkEquity, travel, unamortized, unpredictable

From filing 10-Q 2021 Q1